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We studied HIV genetic diversity in a cohort of 127
pregnant, HIV-infected women who received prenatal care
at Sainte-Justine Hospital in Montreal, Canada, between
1999 and 2003. Clade assignments were derived by phylo-
genetic analysis of amplified pol sequences. Genotyping
was successful in 103 of 127 women, 59 (57.3%) of whom
were infected with clade B HIV-1, and 44 (42.7%) with non-
clade B viruses, including subtypes A, C, D, F, G, and H.
Four sequences remained unassigned. Forty-three of 44
women infected with non-clade B viruses were newcomers
from sub-Saharan Africa, and subtype identity was consis-
tent with those circulating in their countries of origin. These
results highlight the epidemiologic importance of non-B
HIV-1 in antenatal populations in a large North American
urban center, underscore the influence of population move-
ments on clade intermixing, and identify a group of patients
who could be targeted for surveillance and drug therapy fol-
lowup. 
H
IV-1 exhibits considerable genetic diversity resulting
from the high mutation rate of reverse transcriptase,
high viral turnover, viral genomic recombination, and
immune and therapeutic selection pressures (1–3). This
diversity is a challenge for viral load determination, drug
resistance testing, and AIDS vaccine development (1,4–6).
Three phylogenetic groups of HIV-1, main (M), outlier
(O), non-M, non-O (N), are recognized (2,7). Most HIV-1
infections are caused by group M viruses that comprise 9
clades (A–D, F–H, J, and K) and >13 intersubtype recom-
binants known as circulating recombinant forms (CRFs)
(8). Clade B is most common in North America, Europe,
and Australia. However, in the last decade, prevalence of
infection with nonclade B viruses has increased in France,
Belgium, Spain, and Switzerland (9–12), in large part after
migration from or international travel into HIV-endemic
areas (13). Nonclade B viruses also circulate in Cuba (14)
and the United States (15,16). We measured HIV-1 subtype
diversity in a multiethnic cohort of pregnant, HIV-infected
women to determine whether nonclade B HIV-1 is emerg-
ing in Canada after population movement, and whether
antenatal cohorts are suitable sentinel sites to monitor the
introduction of nonclade B viruses into Canada.
Patients and Methods
Patients
One hundred twenty-seven HIV-infected women
receiving prenatal care at Centre Maternel et Infantile sur
le SIDA, Sainte-Justine Hospital, Montreal, from October
1999 to September 2003 were included in the study.
Inclusion criteria were 1) age ≥18 years, 2) a request for
prenatal care, 3) positive HIV-1 serologic results, and 4)
informed consent. Standardized clinical followup, includ-
ing antiretroviral (ARV) prophylaxis and treatment, was
provided to all women and their children. This cohort
study was conducted according to the guidelines of the
Ethics Review Board of Sainte-Justine Hospital.
Clinical Parameters
HIV-1 serologic status was determined by using the
AxSYM HIV 1/2 gO method (Abbott Diagnostics,
Wiesbaden, Germany) and confirmed by Western blot.
HIV-1 viral load was measured by using the Versant HIV-
1 RNA 3.0 assay (bDNA, Bayer, Pittsburgh, PA, USA).
CD4+ T-cell counts were measured by flow cytometry.
Standardized data collection assessed sociodemographic
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Numeric variables were compared by using the Kruskal-
Wallis test. Categoric variables were examined by using
the Fisher exact test (SPSS version 11.0, SPSS, Inc.,
Chicago, IL, USA).
HIV-1 Genotyping
In cases in which viral load was >1,000 RNA
copies/mL plasma, HIV-1 genotyping was performed by
using a protocol (Virco BVBA, Mechelen, Belgium) based
on sequencing of a 1,497-bp fragment of the HIV-1 pol
gene (position 2253-3749). In cases in which viral load
was  <1,000 copies/mL, viral RNA was extracted from
plasma, and a 524-bp pol segment (position 2597–3120)
was amplified by using primers 3069R (5′-GGA TGG
CCC AAA GGT TAA ACA-3′) and 3591F (5′-ATC CTA
CAT ACA AAT CAT CCA T-3′) and the QIAamp 1-step
reverse transcription–polymerase chain reaction (RT-PCR)
method (Qiagen, Mississauga, Ontario, Canada). PCR
conditions were 40 cycles consisting of 94°C for 30 s,
53°C for 1 min, and 72°C for 1 min, followed by extension
at 72°C for 10 min. Amplicons were cloned into pPCR-
Script (Stratagene, La Jolla, CA, USA) and sequenced by
using dye terminator chemistry (Beckman-Coulter, Palo
Alto, CA, USA). 
Sequences were aligned with references (2001) repre-
senting different HIV-1 subtypes (http://hiv-web.lanl.gov)
(8) by using Clustal X version 1.81 (17). Kimura 2-param-
eter distance matrices were assembled (transition/transver-
sion ratio of 2) (18,19). Phylogenetic reconstructions were
built according to the neighbor-joining method, and 1,000
bootstrap resamplings were performed to assess tree topol-
ogy (MEGA version 2.1) (20). Clade assessment was
based on reliable grouping (>80% bootstrap) with refer-
ence sequences (8). RIP version 1.9 (www.hiv.lanl.gov/
content/hiv-db/RIPPER/rip_test.html) (21) was used to
examine potential intersubtype recombinants, with gap
stripping on, a window size of 200 characters, and a signif-
icance threshold of 90%.
Results
One hundred twenty-seven women 18.3–42.6 years of
age (median 30.9, interquartile range [IQR] 7.2) were
included in the study: 40 (31.5%) from North and Central
America, 35 (27.6%) from the Caribbean, 1 (0.8%) from
Asia, and 51 (40.2%) from sub-Saharan Africa. Median
HIV-1 viral load at the time of inclusion in the study was
3.24 log RNA copies/mL of plasma (IQR 1.97) and medi-
an CD4+ cell count was 403 cells/µL (IQR 248). Of the
127 patients, 66 (52.0%) had not received ARV therapy
before study inclusion, 8 (6.3%) had interrupted therapy,
and 53 (41.7%) were treated with a regimen consisting of
1 (n = 2), 2 (n = 9), 3 (n = 39) or 4 (n = 3) ARV drugs.
The HIV-1 pol gene was successfully amplified and
sequenced in 103 (81.1%) of 127 patients, a rate compara-
ble with findings of other studies (22). Seventy-three
results were obtained with the Virco procedure, and 30
were obtained with an alternative RT-PCR method.
Unsuccessful amplification was associated with low viral
load: patients with a viremia level of <500 copies/mL
accounted for 23 (95.8%) of 24 in whom gene amplifica-
tion was unsuccessful, in comparison with 27 (26.2%) of
103 in the rest of the study group (p<0.0004, Fisher exact
test). This is consistent with the finding that a larger pro-
portion of patients with unsuccessful gene amplification
were treated with ARV therapy at the time of inclusion in
the study (75.0% versus 34.0%, p<0.0004, Fisher exact
test). Despite this limitation, sequence information was
obtained in more than half of patients with a viremia level
of <500 copies/mL (27/50), and in one third of patients
with a viremia level of <50 copies/mL (8/24). 
Phylogenetic analysis based on a 524-bp pol fragment
(position 2597–3120) was used to identify the HIV-1
clade. In all cases, grouping based on the 524-bp fragment
was consistent with that obtained when all available 1,497-
bp sequences were analyzed separately (data not shown).
In aggregate analysis, sequences derived from 59 (57.3%)
of 103 patients formed a well-defined cluster with clade B
reference sequences (Figure, left panel and data not
shown). Of these 59 patients, 27 (45.8%) were of Canadian
origin, 27 (45.8%) were from Haiti, 2 (3.4%) from
Mexico, 1 (1.7%) from Jamaica, 1 (1.7%) from the
Dominican Republic, and 1 (1.7%) from the United States.
Phylogenetic overlap between these sequences was con-
siderable, and bootstrap support for clustering based on
country of origin was <50% (Figure, left panel). 
In addition, 44 (42.7%) of 103 patients were infected
with nonclade B viruses. Nine (20.5%) of the amplified
sequences were similar to reference sequences from clade
A, including CRF01-AE. Within this cluster, independent
grouping of sequences derived from patients TV641,
TV731, and TV783 was only supported by low bootstrap
values (Figure, right panel). Sequences from 12 patients
(27.3%) clustered alongside clade C references (93% boot-
strap), with TV833 the distal taxon. Five (11.4%) grouped
with clade D. Two (4.55%) grouped with clades F1 and F2,
with TV633 closest to the CRF05-DF reference. One
sequence (2.27%) grouped with clade H (99% bootstrap),
and 11 (25.0%) with clade G. Among these, 8 sequences
formed a well-supported CRF02-AG subcluster (97%
bootstrap), while TV909 grouped closest to clade G refer-
ence (96% bootstrap). TV737 and TV695 formed a distinct
G clade subcluster (100% bootstrap) (Figure, right panel).
The 938-nucleotide (nt) fragments of the envelope (env)
gene V1-V3 region were amplified, sequenced, and ana-
lyzed in samples from patients TV737 and TV695. These
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strap) but loosely with clade G references (41% bootstrap),
which confirmed that these 2 isolates fall outside of the
subtype G crown group (data not shown). Finally, TV721
and TV749 clustered loosely with the J reference (61%
bootstrap), while TV725 and TV919 grouped outside
major clades, although all belonged to the M group (100%
bootstrap) as determined by phylogenetic analysis using
group N, O, U, and SIVcpz alignments (8) (not shown). 
In patients in whom the 1,497-nt sequences were avail-
able, the potential intersubtype mosaic nature of viruses
with uncertain clade assignment was examined using RIP
(21). This analysis indicated that TV731 and TV783 had
significant homology with the A1 + A2 consensus, TV833
was homologous to the clade C reference, and TV737 and
TV909 closely resembled the clade G consensus (>90%
confidence), which confirmed initial assessments. The
recombinant nature of TV633 was also supported, with
significant homology to clades D and F (putative crossover
at position 2795–2796), while TV695 showed highest
resemblance to clade G in its 5′-terminal portion and clade
C at the 3′ end (>90% confidence), with a potential break-
point at position 3169–3170. In addition, TV721, TV725,
TV749, and TV919 did not show significant homology
with any of the sequences in the reference alignment,
which prevented assessment of their putative intersubtype
nature and their assignment to existing M group clades
(Figure, right panel and data not shown). TV721 and
TV749 were compared with HIV sequences in GenBank
using BLAST (http://www.ncbi.nlm.nih.gov/ BLAST/).
The closest homology to TV721 was isolate A2-225.692
from Uganda (23), with 92% identity over a 522-nt seg-
ment. The closest homology to TV749 was isolate
97CM.MP806 from Cameroon (24), with 89% identity
over an 884-nt segment. When the 938-nt segments of the
env gene V1-V3 region were amplified and sequenced,
TV721 and TV749 clustered closely with one another
(100% bootstrap) and with clade G and J references (92%
bootstrap) (data not shown). This finding suggests that
TV721 and TV749 represent either complex mosaic
recombinants or a new subtype of the HIV-1 M group.
In all but 1 patient (43 [97.7%] of 44), those infected
with nonclade B viruses were newcomers from Africa,
including 34 (77.3%) asylum seekers. Nine patients origi-
nated from West Africa: Côte d’Ivoire (n = 4), Burkina Faso
(n = 1), Guinea (n = 2), Ghana (n = 1), and Nigeria (n = 1).
Twenty-five originated from central Africa: Congo (n = 7),
Democratic Republic of Congo (n = 3), Rwanda (n = 7),
Burundi (n = 4), Cameroon (n = 3), and Chad (n = 1). Four
originated from East Africa: Ethiopia (n = 3) and Eritrea
(n = 1). Four originated from southern Africa: Zimbabwe
(n = 3) and Madagascar (n = 1). One patient declined to
specify her country of origin. Geographic clustering was
observed on the cladogram, with West African sequences
grouping among clade G, and East and southern African
sequences grouping with clade C. The highest HIV-1 genet-
ic diversity was observed in patients from central Africa
(Figure, right panel), as previously reported (25).
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Figure. Phylogenetic analysis of pol
sequences derived from pregnant women
infected with HIV-1. Trees were construct-
ed by using the neighbor-joining method
as described in Patients and Methods. A
transition/transversion ratio of 2 was used
and 1,000 bootstrap resamplings were
performed. Left panel: Subgrouping with
clade B HIV-1. Right panel: Grouping with
non-B HIV. Reference sequences (REF)
were obtained from the Los Alamos
National Laboratory database (2001) (8).
The scale bar represents 0.02 nucleotide
substitutions per site. Letter codes indicate
country of origin. All nucleotide sequence
information was submitted to GenBank
(accession no. DQ059647-DQ059749).
CRF, circulating recombinant form.Median viral load and CD4+ cell count at the time of
inclusion in the study were not significantly different in
patients infected with clade B virus versus those infected
with nonclade B virus, although more patients infected
with clade B virus received ARV therapy. In patients not
treated, median CD4+ cell count was 91 cells/µL lower in
those infected with nonclade B virus, which suggests more
advanced disease (Table). Comparison of duration of
infection between subgroups was not possible.
Discussion
HIV-1 clade diversity was characterized among a
cohort of HIV-infected women receiving prenatal care in a
tertiary care hospital serving a cosmopolitan population.
Results indicate that 59 (57.3%) of 103 patients in whom
genotyping was successful were infected with clade B
HIV-1. This finding is compatible with the wide circula-
tion of clade B in North and Central America and the
Caribbean, from which 40 (31.5%) and 35 (27.6%),
respectively, of the 127 patients in our cohort originated,
and the relatively high prevalence of HIV-1 infection
among patients from Haiti in the Montreal area (1,26).
Additionally, 42.7% of patients in whom genotyping was
successful were infected with nonclade B viruses, a pro-
portion much greater than the rate reported in 312 HIV-
infected US blood donors (2%) (16) and in a recent
Canadian public health surveillance report (8.9%) (27). To
our knowledge, this is the highest prevalence of non-B
HIV infection reported in any North American study
group, including US military personnel (16,28,29).
Sequences were identified that belonged to every clade of
the HIV-1 M group except J and K. This level of genetic
diversity was not previously reported in a North American
study group, with the exception of the Centers for Disease
Control and Prevention surveillance registry (22), and is as
extensive as that observed in Cuba (14). Four of the pol
segments obtained clustered ambiguously among refer-
ence sequences, which suggests that they represent either
novel HIV-1 M group clades or complex recombinants.
However, additional characterization, including full-
genome sequencing, would be required to settle this issue.
Based on our results, infection with multiple HIV-1 sub-
types cannot be reliably assessed. 
A total of 97.7% of non-clade B viruses were found in
African women and, in all cases, clade identity was consis-
tent with variants circulating in the patient’s area of origin
(1). No significant difference was found between the pro-
portions of African women in patients with unsuccessful
amplification (8 [33.3%] of 24) versus those in whom
amplification was successful (43 [41.7%] of 103, p =
0.496, Fisher exact test), which is indicative of no selec-
tion bias. Recent armed conflicts in the African subconti-
nent have led to an influx into Canada of newcomers from
HIV-endemic areas (30,31). Among our study group, dates
of arrival into Canada of patients infected with nonclade B
HIV-1 correspond with the migration of refugees after the
Rwandan genocide and the civil war in the former
Republic of Zaire and neighboring Congo (data not shown)
(30,31). Nonclade B viruses have spread in Europe and
Cuba as a consequence of international travel and immi-
gration from Africa (9–14). Our study demonstrates that
multiple HIV-1 clades are being introduced under similar
circumstances in a large, North American urban center.
From a public health standpoint, antenatal cohorts could
represent an important sentinel site to monitor the influx of
novel HIV-1 variants in industrialized countries. 
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